Eidos Therapeutics (Eidos Therapeutics) Inventory Turnover : 0.00 (As of Sep. 2020)

View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Eidos Therapeutics's Cost of Goods Sold for the three months ended in Sep. 2020 was $0.00 Mil. Eidos Therapeutics's Average Total Inventories for the quarter that ended in Sep. 2020 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Eidos Therapeutics's Inventory-to-Revenue for the quarter that ended in Sep. 2020 was 0.00.

Eidos Therapeutics Inventory Turnover Historical Data

The historical data trend for Eidos Therapeutics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics Inventory Turnover Chart

Eidos Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Inventory Turnover

Eidos Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Inventory Turnover	Get a 7-Day Free Trial											-	-	-	-	-

Eidos Therapeutics Inventory Turnover Calculation

Eidos Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2019 is calculated as

	Inventory Turnover (A: Dec. 2019 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2019 )	/ (	(Total Inventories (A: Dec. 2018 )	+	Total Inventories (A: Dec. 2019 ))	/	count )
=	2.5	/ (	(0	+	0)	/	1 )
=	2.5	/	0
=	N/A

Eidos Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2020 is calculated as

	Inventory Turnover (Q: Sep. 2020 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Sep. 2020 )	/ (	(Total Inventories (Q: Jun. 2020 )	+	Total Inventories (Q: Sep. 2020 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Eidos Therapeutics (NAS:EIDX) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Eidos Therapeutics's Days Inventory for the three months ended in Sep. 2020 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2020 )	/	Cost of Goods Sold (Q: Sep. 2020 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Eidos Therapeutics's Inventory to Revenue for the quarter that ended in Sep. 2020 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2020 )	/	Revenue (Q: Sep. 2020 )
	=	0	/	0.127
	=	0.00

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Eidos Therapeutics Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Eidos Therapeutics (Eidos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (NAS:EIDX) » Definitions » Inventory Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104

Website

https://www.eidostx.com

Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.

Executives

Uma Sinha	director, officer: Chief Scientific Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Franco Valle	officer: Senior Vice President, Finance	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Cameron Turtle	officer: Chief Business Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Jonathan C Fox	officer: See Remarks	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Sawochka Hooper	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Douglas Rohlen	director	3600 HOLLY LANE NORTH, SUITE 40 PLYMOUTH MN 55447
Eric Aguiar	director	888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Rajeev M. Shah	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali J. Satvat	director, 10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO., 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Christine Siu	officer: CFO and Secretary	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Bridgebio Pharma, Inc.	10 percent owner	421 KIPLING STREET PALO ALTO CA 94301
Neil Kumar	director, 10 percent owner, officer: Chief Executive Officer	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Hoyoung Huh	director	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116